Ductal Carcinoma in Situ (DCIS) is a condition where the cells lining the milk ducts (the channels in the breast that carry milk to the nipple) are cancerous, but stay contained within the ducts without growing through into the surrounding breast tissue. DCIS may affect just one area of the breast, but can be more widespread and affect different areas at the same time. Sometimes DCIS may be described as pre-cancerous, pre-invasive, non-invasive, or intraductal cancer.
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments, according to a research letter by Zehra B. Omer, B.A., of Massachusetts General Hospital—Institute for Technology Assessment, Boston, and colleagues.
The ductal carcinoma in situ Score quantifies the risk of ipsilateral breast event and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to improve the process of selecting individualized treatment for women with DCIS who meet the criteria, according to a study published May 2 in the Journal of the National Cancer Institute.
Because members of Congress are accustomed to high-quality medical care provided to them through federal employee benefit programs, one might expect that they would push for top quality care to be delivered through the exchanges too.
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found.
Tomosynthesis (3D mammography) is better able to show infiltrating ductal carcinoma than 2D mammography in women at increased risk of breast cancer, a new study shows.
Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).
Today, patients with precancerous lesions, or early-stage breast cancer are usually diagnosed after a mammography screening. This method of detection can lead to false-positives and overtreatment, since mammography cannot determine whether pre-cancerous cells will actually turn into breast cancer. This may all change after Sidney Fu, M.D., professor of medicine at the George Washington School of Medicine and Health Sciences (SMHS), completes his study of early breast cancer detection using novel small RNA (microRNA or miRNA) biomarkers.
New research from the Netherlands shows that the switch from screen film mammography (SFM) to digital mammography (DM) in large, population-based breast cancer screening programs improves the detection of life-threatening cancer without significantly increasing detection of clinically insignificant disease. Results of the study are published online in the journal Radiology.
A receptor protein suppresses local invasion and metastasis of breast cancer cells, the most lethal aspect of the disease, according to a research team headed by scientists from The University of Texas MD Anderson Cancer Center.
Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation Oncology-Biology-Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Breast brachytherapy with a strut-based applicator appears to be an effective treatment for women who have ductal carcinoma in situ (DCIS) of the breast, according to a groundbreaking study presented at the annual meeting of the American Society of Breast Surgeons, held in Phoenix May 2-4.
Radiotherapy treatment (RT) after surgery for ductal carcinoma in situ (DCIS) still has a major protective effect against recurrence more than 15 years later, according to the results of an international trial.
Women diagnosed with ductal carcinoma in situ (DCIS) need clear communication and tailored support to enable them to understand this complex breast condition, which has divided the medical profession when it comes to its perception and prognosis.
Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology.
Researchers have discovered a restricted pattern of molecules that differentiate early-stage breast tumors from invasive, life-threatening cancer. They also found a similar molecular signature that correlated with the aggressiveness of invasive tumors, and with the time to metastasis and overall survival.
Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.
In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).
Mammograms should not be done on a one-size fits all basis, but instead should be personalized based on a woman's age, the density of her breasts, her family history of breast cancer and a number of other factors including her own values.
In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.